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Antiviral immune response in patients with multiple sclerosis
and healthy siblings
Abstract
The objective of this study was to determine the immune responses to candidate viral triggers of
multiple sclerosis in patients and healthy siblings raised in the same family household. Virus
antigen-specific IgG responses to Epstein-Barr virus-derived gene products as well as to human
herpersvirus-6, human cytomegalovirus, and measles virus were evaluated in 25 multiple sclerosis
patients and compared with 49 healthy full-siblings. IgG responses to the latent Epstein-Barr
virus-encoded nuclear antigen-1 (EBNA1) were selectively increased in individuals with multiple
sclerosis compared with their unaffected siblings. We conclude that elevated IgG responses towards
EBNA1 are associated with the development of multiple sclerosis.
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Abstract 
Objectives  
To determine the immune responses to candidate viral triggers of multiple 
sclerosis (MS) in patients and healthy siblings raised in the same family 
household.   
Methods  
Virus antigen-specific IgG responses to Epstein-Barr virus (EBV)-derived gene 
products as well as to human herpersvirus-6, human cytomegalovirus, and 
measles virus were evaluated in 25 MS patients and compared to 49 healthy full-
siblings.  
Results  
IgG responses to the latent EBV-encoded nuclear antigen-1 (EBNA1) were 
selectively increased in individuals with MS compared with their unaffected 
siblings.  
Conclusion  
The increase of IgG responses towards EBNA1 is specifically associated with the 
development of MS.   
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Introduction 
Investigating host-pathogen interactions in patients with multiple sclerosis (MS) 
compared to unaffected siblings who were likely exposed to similar 
environmental factors during childhood/adolescence provides the opportunity to 
determine antiviral immune responses specifically associated with the 
development of MS. Here, we determined antibody responses to ubiquitous 
viruses previously associated with MS in untreated patients and healthy siblings 
raised in the same family household.   
 
 
Patients and Methods   
Twenty-four untreated patients with a diagnosis of definite MS (21 with relapsing-
remitting MS, 2 with primary-progressive MS and 1 with transitional progressive 
MS), one patient with a clinically isolated syndrome, and 49 healthy full-siblings 
were included in the study. The study was approved by the local ethics 
committee and all the subjects involved in the study gave written informed 
consent. A summary of demographic and clinical characteristics of patients and 
siblings is shown in Table 1. 
Virus antigen-specific IgG responses were assessed using commercially 
available ELISA kits according to the manufacturers’ recommendations. The 
following kits were used: Epstein-Barr nuclear antigen 1 (EBNA1) (p72) IgG for 
the detection of antibody responses towards the immunogeneic C-terminal 
domain of EBNA1 (Biotest, Dreieich, Germany), EBV-viral capsid antigen (VCA) 
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(p23/p28) IgG (Diamedix Corporation, Miami, USA), human cytomegalovirus 
(HCMV) and measles virus (viral lysates) IgG (both from BioMerieux, Marcy-
l'Etoile, France), as well as human herpesvirus 6 (HHV-6) (viral lysates) IgG 
(Panbio, Brisbane, Australia). The manufacturer’s cut-off value for presence of 
virus-specific antibodies was used. 
EBV DNA was quantified from peripheral blood mononuclear cells (PBMC) by 
quantitative real time PCR in triplicates using a TaqMan PCR kit and a Model 
7500 Sequence
 
Detector (Applied Biosystems, Foster City, CA) as described 
previously [1].  
 
   
Results 
As expected, seroprevalence rates of EBV, HHV-6, HCMV, and measles virus 
infections were similar in patients and non-affected siblings (Figure 1). 
However, individuals with MS differed from their siblings in showing markedly 
increased IgG responses to the C-terminal domain of EBNA1 (p = 0.0007; 
Mann-Whitney U test). IgG responses to pooled HHV-6 antigens also tended 
to be higher in some patients (p = 0.014; Mann-Whitney U test), but EBNA1 
remained the only differentially recognized viral antigen following Bonferroni 
correction (alpha = 0.01). IgG responses to EBV-encoded lytic viral capsid 
antigens as well as to pooled HCMV- and measles virus-derived antigens were 
similar in patients with MS and siblings (Figure 1). Given the saturating 
specific absorbances of EBNA1-specific IgG reactivities in MS patients, we re-
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performed both EBV ELISAs using diluted serum samples (1:5) and could 
reproduce our findings of increased EBNA1-specific IgG responses in MS 
(Figure 2). To determine whether the increased immune response to EBNA1 
correlate with higher viral loads, we additionally quantified levels of cell-bound 
viral genomes in circulating blood cells by real time PCR using bcl-2 DNA 
controls [1]. EBV DNA was detectable in 9 out of 15 (60%) patients from whom 
PBMC were accessible for viral load quantification and in 8 out of 15 (53%) of 
their healthy siblings. Viral loads did not differ significantly between the two 
groups (median viral titers per 106 PBMC in patients vs. siblings:  59.7 vs. 
96.4, p = 0.9; Mann-Whitney U test).  
 
 
Discussion 
Although raised within the same family microenvironment, patients with MS differ 
from their siblings in their increased IgG response to EBNA1, the most 
consistently recognized EBV-derived CD4+ T cell antigen in healthy virus carriers. 
High IgG activity to EBNA-1 has been found to be associated with an increased 
risk to develop MS in several studies with sera collected many years before 
onset of MS (1) and a predominant or selective increase of immune responses to 
EBNA1 has previously been documented in various independent MS populations 
(ref. #1 and 5). The mechanisms responsible for these changes in EBV-specific 
immunity are not well understood. Three main scenarios have been proposed: (i) 
Infection with an MS-specific EBV strain leads to increased or altered immune 
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responses to EBNA1. We consider this possibility unlikely since we assume that 
patients and siblings included in our study are infected with similar strains of 
EBV. (ii) Host factors predisposing for MS, such as allelic variants of susceptibility 
genes, favor the presentation and recognition of a particular viral antigen such as 
EBNA1. Environmental factors clearly require a permissive genetic trait to trigger 
MS since studies in twins, siblings and adopted relatives of MS patients found no 
indication for non-genetic transmissibility of the disease [7,8]. Full-siblings, as 
studied here, share only 50% of their genes and we cannot exclude the 
possibility that genetic factors contribute to increased immune responses to 
EBNA1. However, it appears unlikely that allelic variants of proteins with general 
immune functions such as HLA-DR alleles or single nucleotide polymorphisms in 
IL2RA and IL7RA genes are exclusively responsible for the predominant 
increase of EBNA1-specific immune responses in MS. (iii) Increased EBNA1-
specific IgG responses are maintained by persisting clonal expansions of 
polyspecific T cells recognizing both central nervous system autoantigens and 
EBNA1. In support of this hypothesis, patients with MS show selective 
expansions of T cells specific for EBNA1 which recognize myelin antigens more 
frequently than other autoantigens that are not associated with MS [1,6]. The 
finding that cell-associated viral loads are not increased patients with MS 
suggests that crossreactivity to autoantigens could augment EBNA1-specific 
CD4+ T-cell responses.  
We conclude that the prominent increase of EBNA1-specific IgG responses is 
specifically associated with the development of MS and unlikely due to infection 
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with an MS-specific EBV strain acquired within the family microenvironment.  
Further studies are necessary to elucidate the mechanisms by which altered 
immune responses to EBNA1 could potentially contribute to the pathobiology of 
MS. 
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Figure Legend 
 
Figure 1. Increased EBNA1-specific IgG responses in patients with MS 
compared to healthy siblings raised within the same family household. 
Seroprevalence rates of EBV, HHV-6, HCMV, and measles virus infections were 
similar in patients and non-affected siblings and are given below the diagrams. 
IgG reactivities are expressed as OD values (specific absorbance) or titers (for 
HCMV) according to the manufacturers’ recommendations.  Following Bonferroni 
correction for multiple testing, EBNA1 is the only differentially recognized viral 
antigen in patients with MS (p = 0.0007; Mann-Whitney U test). 
 
Figure 2. Rerun of the EBV ELISAs with diluted samples (1:5). 
Seroprevalence rates are given below the diagrams. IgG reactivities are 
expressed as OD values (specific absorbance). MS patients show increased IgG 
reactivities to EBNA1 but not to EBV-VCA (p = 0.0002; Mann-Whitney U test). 
 
 
 
 
Table 1. Demographic and baseline clinical characteristics of patients and healthy 
siblings  
 
 
 
 
 
 
 
 
 
a
Data are expressed as mean (standard deviation). 
b
Data are expressed as median 
(interquartile range). *Refers to patients with relapsing-remitting and secondary 
progressive MS. PP: primary progressive MS. TP: transitional progressive MS. CIS: 
clinically isolated syndrome. 
 
 
 
 
 
 
 
 
 
Characteristics Patients Siblings 
n 25 46  
Age (years)
a
 36.2 (10.7) 36.3 (12.8) 
Female/male (% women)
 
 16/9 (64.0) 24/22 (52.2) 
Clinical form 21 Relapse-onset* /  
2 PP / 1 TP / 1 CIS 
- 
EDSS
 b
 2.5 (1.5 - 4.0) - 
Duration of disease
a
 6.9 (5.4) - 
MS PATIENTS HEALTHY SIBLINGS
0
1
2
3
4
EBNA1-IgG
*
MS PATIENTS HEALTHY SIBLINGS
0
2
4
6
EBV-VCA-IgG
MS PATIENTS HEALTHY SIBLINGS
0
2
4
6
HHV6-IgG
MS PATIENTS HEALTHY SIBLINGS
0
2
4
6
MEASLES-IgG
MS PATIENTS HEALTHY SIBLINGS
0
100
200
300
400
HCMV-IgG
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